1 body specificity and titer were defined by a
microneutralization and a pseudotype assay that could as
2 Serum samples were tested with
microneutralization and hemagglutination inhibition assa
3 d vaccination were tested for H5 antibody by
microneutralization and hemagglutination inhibition.
4 ibody positive if they were positive by both
microneutralization and Western blot testing.
5 In plaque reduction,
microneutralization,
and fusion-inhibition assays, MEDI-
6 A 2.7- and 3.5-fold rise in RSV/A and RSV/B
microneutralization antibodies were noted at day 56.
7 nced seroconversion rates and geometric mean
microneutralization antibody titers.
8 vaccine titer as assessed through a standard
microneutralization assay (p<0.05, q <0.2).
9 ed 18 to 59 years were achieved by using the
microneutralization assay combined with Western blotting
10 Direct comparison of an HI assay and the
microneutralization assay demonstrated that the latter w
11 We have developed an alternative
microneutralization assay for influenza virus using a qu
12 P)-based approach to develop a vaccine and a
microneutralization assay for ZIKV.
13 ibition and microneutralization assays, with
microneutralization assay titers >40 considered positive
14 was tested using a quantitative colorimetric
microneutralization assay to demonstrate antibody titers
15 Therefore, we developed a more sensitive
microneutralization assay to detect antibodies to avian
16 A
microneutralization assay using an ELISA-based endpoint
17 Microneutralization assay was as sensitive as rtRT-PCR i
18 The sensitivity of the GFP-based
microneutralization assay we developed was similar to th
19 The sensitivity and specificity of the
microneutralization assay were compared with those of an
20 The RVP-based
microneutralization assay worked similarly to the PRNT a
21 ase chain reaction (rtRT-PCR), and serology (
microneutralization assay).
22 lizing antibody responses were measured by a
microneutralization assay, and hemagglutinin (HA)-specif
23 parable to that obtained by the conventional
microneutralization assay, suggesting that the use of th
24 Using a
microneutralization assay, we measured cross-reactive an
25 lizing antibody titers were measured using a
microneutralization assay.
26 postpartum and tested using an RSV antibody
microneutralization assay.
27 bition (HI) assay and, for a subset, also by
microneutralization assay.
28 to test for H5N1 neutralizing antibodies by
microneutralization assay.
29 mock-treated control ferrets, as assessed by
microneutralization assay.
30 d for their ability to neutralize virus in a
microneutralization assay.
31 with a clade 1 vaccine were characterized by
microneutralization assays and modified hemagglutination
32 We recently developed high-throughput virus
microneutralization assays using an endpoint assessment
33 cted in ELISA, hemagglutinin-inhibition, and
microneutralization assays with these monoclonal antibod
34 (i.e., from hemagglutination inhibition and
microneutralization assays) and HA protein sequences.
35 by means of hemagglutination inhibition and
microneutralization assays, with microneutralization ass
36 measured by hemagglutination inhibition and
microneutralization assays.
37 ssessed in hemagglutination inhibition (HI),
microneutralization,
ELISA, lymphoproliferative, ELISpot
38 The
microneutralization GMTs after the first, second, third,
39 lt in higher hemagglutination inhibition and
microneutralization GMTs, compared with the GMTs resulti
40 on and 227 nonexposed U.S. individuals using
microneutralization (
MN) and hemagglutination inhibition
41 Microneutralization (
MN) and hemagglutination-inhibition
42 Hemagglutination inhibition (HAI) and
microneutralization (
MN) antibodies were measured on day
43 by hemagglutination inhibition (HAI) assay,
microneutralization (
MN) assay, and a newly standardized
44 ated by hemagglutination inhibition (HI) and
microneutralization (
MN) assays, H7 viruses and vaccines
45 y hemagglutination inhibition (HI) and virus
microneutralization (
MN) assays.
46 ults of hemagglutination inhibition (HI) and
microneutralization (
MN) assays.
47 ains by hemagglutination inhibition (HI) and
microneutralization (
MN) assays.
48 ed with hemagglutination inhibition (HI) and
microneutralization (
MN) titers (all P < 0.001).
49 crog dose of A/Vietnam vaccine induced virus
microneutralization (
MN) titers of >/=1:20 against the A
50 HI titers,
microneutralization (
MN) titers, and the frequency of ci
51 red by the hemagglutination inhibition (HI),
microneutralization (
MN), and single radial hemolysis (S
52 Antibody persistence (defined as
microneutralization [
MN] titer >/=1:40) 1 year after ini
53 A simplified
microneutralization procedure is described that uses an
54 in standard hemagglutination inhibition and
microneutralization serological assays.
55 sing enzyme-linked immunosorbent assays or a
microneutralization test.
56 Microneutralization titers tended to be higher than HAI
57 ELISA and
microneutralization titers were concordant.
58 Hemagglutinin inhibition (HI) responses,
microneutralization titers, and antineuraminidase antibo
59 surement of haemagglutination inhibition and
microneutralization titres.